BrainTale’s Post

A significant portion of biopharma investments goes towards clinical development, where success is critical for regulatory approval and market readiness. When engaging with investors, aligning your clinical development strategy with their priorities—time, cost, and success probability—can make all the difference. Join experts like Dr. Bruce Leuchter, M.D., CEO of Neurvati Neurosciences), Dr. Michael Panzara, CMO of Neurvati Neurosciences), and Dr. Natalia Mühlemann,VP Strategic Consulting at Cytel, in an insightful webinar. Learn how adaptive approaches and Bayesian methods can enhance your clinical program and make it more attractive to investors. 💼💡 Register here 👉https://hubs.ly/Q02TDshh0 #ClinicalDevelopment #Biopharma #InvestingInInnovation #AdaptiveDesign #BayesianMethods #Biotech

An interesting upcoming webinar on how adaptive trial design and Bayesian methods can enhance your clinical program to make more attractive to investors.

I really enjoyed sharing the Immunophotonics, Inc. story at the Global Life Science Partnering and Investor Conference hosted by Biocom California as well as exploring future collaborative opportunities at the The National Institutes of Health with Dr. Brad Wood and the #interventionaloncology team! Thanks again to the NIH for sponsoring our presentation at Biocom24. Michael Weingarten, Brittany Connors, PMP: Your team is doing wonderful work that makes a real difference in innovation. Thank you. Regarding the conference: Great meetings with potential investors and good advice from the panels. For example, panelists from the "Trends in Traditional and Strategic Venture Investing" session, moderated by Daniel Parisotto, PhD @ Oppenheimer & Co. Inc. provided frank advice: -          Kim Kamdar, Think hard about spending allocations -          Mira Chaurushiya, Be intentional with hires and investor selection -          Dalton Einhorn, Figure it our internally before sharing externally -          Andy Schwab, Talk to clinicians -          Mitchell Mutz, Ph.D., It’s all about data My advice (take it or leave it as I certainly don't have a CV to match the panelists!!!): Pivot quickly and push your core programs forward as aggressively as possible. Even small continuous action adds up to big results. #cancerresearch #oncologyinnovation #markettrends #startupinvesting #venturecapital #IIO #researchcollaboration #pharma #biotech #healthcare #cancer

Enabled through our fantastic global partnerships, Lifebit has reached a significant milestone by curating a multi-omic and health data catalog encompassing over 100 million patients worldwide. Aimed at pharma companies requiring deep, diverse data at scale to speed up drug development and clinical trials, Lifebit’s data catalog is pivotal for advancing precision medicine. The comprehensive data covers over 200 health conditions, including critical disease areas like cancer, cardiovascular, respiratory, neurological, diabetes, and rare diseases. Why is this important? 1. Traditional processes for drug development are slow and inefficient, reliant on wet labs 2. Since the 1950s R&D efficiency has declined, with an 80-fold drop in drug productivity and cost of new drugs doubling every 9 years (https://lnkd.in/eC7FExsc) 3. Data is an enabler in driving productivity in drug development (https://lnkd.in/eq65EWzg) This milestone aligns with the recent launch of Lifebit's Platform 2.0, an advanced federated research environment designed to maximize research discoveries while ensuring data privacy and security. For more details about our extensive data catalog: https://bit.ly/3wDYP27 #PrecisionMedicine #Biotech #DataInnovation #Lifebit

"NTI has proven in Phase II trials that its product is safer and just as effective as Neuren’s product for treating Rett Syndrome... With $11.6M in the bank and solid clinical data, NTI is ready to find partners that can take its product to the next level."   Neurotech International Ltd (ASX:NTI) is entering a pivotal phase, transitioning from clinical trials to securing strategic partnerships. With positive Phase II results for NTI164 across three neurological disorders, NTI is now well-positioned to seek global partners to advance its product into the US, Europe, and Asia.   As the biotech industry witnesses billion-dollar deals, NTI's progress could lead to significant market opportunities. Read the latest Investment Memo by Next Investors for more info: https://lnkd.in/gSpq9YZK   #NeurotechInternational #Biotech #ASX #InvestmentNews #ClinicalTrials #NeurologicalDisorders #NTI164 #DealMaking #PharmaPartnerships #OrphanDrug #NTI

David Smith, Vice President of Development at BioCentriq, emphasized the crucial role of CAR-T cells in the collaboration aimed at tackling manufacturing bottlenecks. CAR-T therapies represent a cutting-edge approach in the realm of personalized medicine, offering promising avenues for treating various diseases, particularly cancer. However, the complexities associated with manufacturing CAR-T cells have posed significant challenges, impacting patient access to these innovative treatments. Through the partnership with Terumo Blood and Cell Technologies, BioCentriq is strategically leveraging advanced platforms to address these hurdles. By optimizing manufacturing processes specifically tailored for CAR-T cells, BioCentriq aims to enhance efficiency, scalability, and reliability in producing these transformative therapies. This collaboration underscores BioCentriq's dedication to advancing CAR-T cell therapy by overcoming manufacturing barriers, ultimately ensuring broader patient access and accelerating the development of next-generation treatments. CAR-TCR Summit Series #immunotherapy #cartcelltherapy #cartcrsummitseries #cancerresearch #cancertreatment #tcrtherapy #innovation

We're thrilled to announce the launch of the Keystone LifeSci Collaborative, bringing together key regional stakeholders, including industry leaders, research institutions, and public and community organizations to foster collaboration, innovation, and growth in the life science sector across six Southeastern Pennsylvania counties: Philadelphia, Montgomery, Bucks, Delaware, Chester, and Berks. The inaugural meeting took place on March 6, 2024, where over 30 leaders from the region’s life sciences companies and institutions, including Adaptimmune, Century Therapeutics, Inc, Integral Molecular, Iovance Biotherapeutics, Inc., LAMPIRE Biological Laboratories, Inc., and VintaBio, participated in a facilitated discussion about opportunities for industry growth, stability, and vitality in Southeastern PA. The group focused on the region’s unique advantages and identified five priorities for action to coalesce around, including strengthening business-to-business connectivity, developing a coordinated strategy for building a talent pipeline, influencing policy, raising awareness of life sciences careers, and marketing the region as a life sciences hub. Following the meeting, more than 50 public and community partners, including the University City Science Center, Montgomery County Community College, Drexel University, CIC Philadelphia, Bucks County Community College, the Philadelphia Education Fund, Philadelphia Department of Commerce, and representatives of U.S. Senator Robert P. Casey, Jr. convened for a strategic discussion to better understand how to assist and execute on these defined priorities. The Keystone Life Sci Collaborative is supported by new funding from the American Rescue Plan’s Good Jobs Challenge through our partners at Philadelphia Works, Inc. and aims to address ongoing shared business priorities and enhance regional competitiveness in the life sciences industry. The Collaborative is based on the nationally recognized “Next Gen Sector Partnership” model, active in over 100 regions and more than 20 states. It is the first of its kind in the Southeastern Pennsylvania region. To learn more or to join the Keystone LifeSci Collaborative: https://lnkd.in/exTdgP8q.

Introducing, MetX. The very foundation of the Metrodora mission consists of bringing together patients, providers, and scientists. Each entity holds a key to unlocking the answers behind complex illnesses. We knew the silos of medicine were hindering advancement, so we set out to try something different. Disrupting an entire industry takes time our patients don’t have. Symptoms are often derailing their dreams in the prime of their lives. We knew we had to work hard and fast. Since opening our doors a year ago, our team has seen hundreds of patients, launched clinical trials, and now we are excited to announce MetX, funded by a grant from the Metrodora Foundation and our visionary donors. This is how we come together to accelerate research, treatment, and cures. Patients are empowered to become partners through Metrodora Connect, a digital health toolkit where sharing health records, questionnaires, and wearable device data means an active role in research. A biorepository will host specimens to advance genetic, antibody, and cellular treatments. While leveraging partnerships with other major medical research organizations, Metrodora Biomics will use these specimens to discover targeted drug therapies. The tools, people, and passion already exist. It’s time they unite. We invite you to get to know MetX and the possibilities for all to make a difference right now. #MetX #MetrodoraFoundation #MetrodoraInstitute #Metrodora #MedicalNews #Medical #Medicine #Healthcare #Research #ComplexIllness #LongCOVID #MECFS #POTS #Migraine #Sjogrens #EDS #MCAS #ChronicPain #Fibromyalgia #Endometriosis #FoodAllergy #IBS #IBD

The Power of Digital Therapeutics in Research Digital therapeutics are not just future tech; they are reshaping clinical trials today! Learn how software-based interventions are improving patient recruitment, remote monitoring, and real-world data collection. Dive into our blog to explore the exciting applications and benefits of digital therapeutics in clinical research. 📊 #DigitalTherapeutics #MedicalResearch #Innovation

🗸 Milestone Unlocked! We are thrilled to announce a pivotal achievement in Cytonics' journey. Our recent submission of the Phase 1 clinical trials protocol to ClinicalTrials.gov marks the commencement of an exhilarating phase in our mission to revolutionize osteoarthritis treatment. This submission is not just a procedural step; it represents years of dedicated research and development, bringing us closer to our first-in-human Phase 1 clinical trial. 🔗 Learn more about our R&D and investment opportunity: invest.cytonics.com The upcoming Phase 1 study is a testament to our team's expertise and dedication. It also underscores our potential to significantly impact the biotechnology sector. As we progress into this new phase, your continued support and investment become even more crucial. The success of this trial will not only elevate our company's standing in the industry but also pave the way for delivering life-changing therapies to the 600M suffering from osteoarthritis. 🌍 A New Era Of Healthcare  We are on the cusp of a new era in biotechnology, and your investment plays a vital role in this journey. By backing our initiative, you are not just investing in a company; you are investing in a future where debilitating diseases like osteoarthritis can be eradicated. Join us in this exciting phase of growth and innovation! Together, we are not just making strides in healthcare; we are making history. #biotechnology #drugdevelopment #arthritis #clinicaltrials #crowdfunding